Cardio Diagnostics Expands Access to Precision Cardiovascular Tests Through Atlas Healthcare Physicians

Cardio Diagnostics Holdings (NASDAQ: CDIO), an AI-powered precision cardiovascular medicine company, announced that Atlas Healthcare Physicians, an independent physician association serving managed care populations across Los Angeles and Orange counties, will provide coverage for the company’s Epi+Gen CHD and PrecisionCHD tests for eligible members with prior authorization. This coverage expansion increases access to physician-ordered blood tests designed to assess coronary heart disease risk and support diagnosis and personalized treatment planning.

According to Cardio Diagnostics, the Epi+Gen CHD test evaluates a patient’s three-year risk of a coronary heart disease event, while PrecisionCHD helps diagnose coronary heart disease and identify its underlying molecular drivers. Both tests are noninvasive blood-based diagnostics that do not require fasting or radiation exposure, supporting broader adoption of precision cardiovascular medicine across community healthcare networks.

This development is significant because it brings advanced genetic and epigenetic testing to a broader patient population within managed care networks. By integrating these tests into routine clinical practice, physicians can make more informed decisions about prevention and treatment strategies, potentially reducing the burden of cardiovascular disease. The partnership with Atlas Healthcare Physicians, which serves diverse communities in two of California's most populous counties, underscores the growing demand for precision medicine approaches in cardiovascular care.

Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease. The coverage expansion is expected to enhance the company's commercial footprint and drive adoption of its tests among community-based physicians.

For more information, visit the company’s newsroom at https://nnw.fm/CDIO. The full press release is available at https://nnw.fm/EFQen.